The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders

Annals of the Rheumatic Diseases

Volumn 68, Issue 3, 2009, Pages 337-344

  Landau, D A ^a   Rosenzwajg, M ^a   Saadoun, D ^a,b   Klatzmann, D ^a   Cacoub, P ^a,b  

^a Unit of Dermatology   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; B CELL ACTIVATING FACTOR RECEPTOR 3; CD19 ANTIGEN; METHYLPREDNISOLONE; PEGINTERFERON ALPHA2B; RIBAVIRIN; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN BINDING; ANTIVIRAL THERAPY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CONTROLLED STUDY; CRYOGLOBULINEMIA; DRUG EFFECT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PREMEDICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REMISSION; TREATMENT RESPONSE; VASCULITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; APOPTOSIS; B-CELL ACTIVATING FACTOR; B-CELL ACTIVATION FACTOR RECEPTOR; B-LYMPHOCYTES; CRYOGLOBULINEMIA; HEPATITIS C, CHRONIC; HUMANS; LIGANDS; LYMPHOMA, B-CELL; MIDDLE AGED; VASCULITIS; YOUNG ADULT;

EID: 61449256106     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2007.085910     Document Type: Article

References (46)

1. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999;42:2204-12.
2. De Re V, De Vita S, Marzotto A, Gloghlni A, Pivetta B, Gasparotto D, et al. Premalignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process, Int J Cancer 2000;B7:211-16.
3. Boyer O, Saadoun D, Abriol J, Dodille M, Piette JC, Cacoub P, et al. CD4+CD25-regulatory T-cell deficiency in patients with hepatitis C-mlxed cryoglobulinemia vasculitis. Blood 2004;103:3428-30.
4. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in unflammation. N Engl J Med 2006;354:610-21.
5. Saadoun D, Bieche I, Malsonobe T, Asselah T, Laurendeau I, Piette JC, et al. Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. Arthritis Rheum 2005;52:2917-25.
6. Gorevic PD, Frangione B. Mixed cryoglobulinemia cross-reactive idiotypes: implications for the relationship of MC to rheumatic and lymphoproliferatlve diseases. Semin Hematol 1991;28:79-94.
7. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and metaanalysis. Gastroenterology 2003;125:1723-32.
8. Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89-94.
9. Saadoun D, Suarez F, Lefrere F, Valensi F, Mariette X, Aouba A, et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV Infection: a new entity? Blood 2005;105:74-6.
10. Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H, et al. Risk of non-Hodgkin lymphoma and lymphoproliferatlve precursor diseases in US veterans with hepatitis C virus. JAMA 2007;297:2010-17.
11. Gisbert JP, Garcua-Buey L, Pajares JM, Moreno-Otero R. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther 2005;21:653-62.
12. Pal S, Sullivan DG, Kim S, Lai KK, Kae J, Cotler SJ, et al. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: Implications of HCV lymphotropism. Gastroenterology 2006;130: 1107-16.
13. Ray RB, Meyer K, Ray R. Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 1996;226:176-82.
14. Moriya K, Fujle H, Shintanl Y, Yotsuyanagl H, Tsutsumi T, lshibashl K, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998;4:1065- 7.
15. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-41.
16. Zuckerman E, Slobodin G, Kessel A, Sabo E, Yeshurun D, Halas K, et al. Peripheral B-cell CD5 expansion and CD81 overexpression and their association with disease severity and autoimmune markers in chronic hepatitis C virus infection. Clin Exp Immunol 2002;128:353-8.
17. Curry MP, Golden-Mason L, Doherty DG, Delgnan T, Norris S, Duffy M, et al. Expansion of innate CD5pos B cells expressing high levels of CD81 In hepatitis C virus infected liver. J Hepatol 2003;38:642- 50.
18. Realdon S, Pontisso P, Adaml F, Trentin L, Noventa F, Ferrari A, et al. High levels of soluble tumor necrosis factor superfamily receptors in patients with hepatitis C virus infection and lymphoproliferatlve disorders. J Hepatol 2001;34:723-9.
19. Zignego AL, Ferri C, Giannelli F, Giannini C, Caini P, Monti M, et al. Prevalence of bcl2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002;137:571-80.
20. Sasso EH, Martinez M, Yarfitz SL, Ghillani P, Musset L, Piette JC, et al. Frequent joining of Bcl-2 to a JH6 gene in hepatitis C virus-associated t(14;18). J Immunol 2004;173:3549-56.
21. Avery DT, Kalled SL, Ellyard JI, Ambrose C, Blxler SA, Thien M, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003;112:286-97.
22. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002;2:465-75.
23. Carter RH, Zhao H, Liu X, Pelletier M, Chatham W, Klmberly R, et al. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 2005;52:3943-54.
24. Bosello S, Pers JO, Rochas C, Devauchelle V, De Santls M, Daridon C, et al. BAFF and rheumatic autoimmune disorders: implications for disease management and therapy, Int J Immunopathol Pharmacol 2007;20:1-8.
25. Krumbholz M, Specks U, Wick M, Kalled SL, Jenne D, Meinl E. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 2005;25:298-302.
26. Szodoray P, Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjogren's syndrome. Scand J Immunol 2005;62:421-8.
27. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004;103:3148- 57.
28. Briones J, Timmerman JM, Hilbert DM, Levy R. BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol 2002;30:135-41.
29. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Ceruttl A. Lymphoma B cells evade apoptosls through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004;172:3268-79.
30. Sene D, Limai N, Ghillani - Dalbin P, Saadoun D, Piette JC, Cacoub P. Hepatitis C virus-associated B-cell proliferation - the role of serum B lymphocyte stimulator (BLyS/ BAFF). Rheumatology (Oxford) 2007;46:65-9.
31. Toubi E, Gordon S, Kessel A, Rosner I, Rozenbaum M, Shoenfeld Y, et al. Elevated serum B-lymphocyte activating factor (BAFF) In chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun 2006;27:134-9.
32. Fabris M, Quartuccio L, Sacco S, De March G, Pozzato G, Mazzaro C, et al. B-lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatltis-C virus infection. Rheumatology (Oxford) 2007;46:37-43.
33. Musset L, Diemert MC, Taibl F, Thi Huong Du L, Cacoub P, Leger JM, et al. Characterization of cryoglobulins by immunoblottlng. Clin Chem 1992;38:798-802.
34. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006;54:192-201.
35. H1-specific variable region determinants recognized by anti-idlotypic monoclonal antibodies G6 and G8. Scand J Immunol 1999;50:14-20.
36. Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, Migone TS, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001;97:198-204.
37. H1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. J Immunol 2005;174: 6532-9.
38. Schaumann DH, Tulscher J, Ebell W, Manz RA, Lauster R. VCAM-1 -positive stromal cells from human bone marrow producing cytokines for B lineage progenitors and for plasma cells: SDF-1, flt3L, and BAFF. Mol Immunol 2007;44:1606-12.
39. Sellam J, Miceli-Richard C, Gottenberg JE, Ittah M, Lavie F, Lacabaratz C, et al. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjogren's syndrome and systemic lupus erythematosus. Ann Rheum Dis 2007;66:790-7.
40. Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L, Ford RJ. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood 2006;107:4540-8.
41. Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, Habermann TM, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004;104:2247-53.
42. Do RK, Hatada E, Lee H, Tourigny MR, Hubert D, Chen-Klang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral Immune response. J Exp Med 2000;192:953-64.
43. Zuckerman E, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E, et al. bcl-2 and immunoglobulin gene rearrangement in patients with hepatitis C virus infection. Br J Haematol 2001;112:364-9.
44. Litinskiy MB, Nardelli B, Hubert DM, He B, Schaffer A, Casali P, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002;3:822-9.
45. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: Insights into a new regulating system of BAFF production. Ann Rheum Dis 2007;66:700-3.
46. Ramanujam M, Davidson A. The current status of targeting BAFF/BLyS for autoimmune diseases. Arthritis Res Ther 2004;6:197-202.